RPPH1-2P

Across TCGA pan-cancer cohorts, RPPH1-2P RNA is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated RPPH1-2P data layer.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher RPPH1-2P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPPH1-2P expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

KIRC, UCEC, and ESCA are the cancer types where RPPH1-2P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Tertile	III,IV	0.272	0.763	<.001	126	view →
UCEC	OS	Tertile	II,III,IV	0.467	0.770	.005	72	view →
ESCA	OS	Tertile	All	0.198	0.872	.003	36	view →
STAD	OS	Tertile	IV	1.000	0.309	.034	27	view →
UCS	DFS	Tertile	All	0.142	0.530	.008	18	view →
BLCA	OS	Tertile	IV	0.141	0.573	.034	9	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RPPH1-2P–KIRC (DFS)

Open the KIRC breakdown →